Department of Hematology, Third Xiangya Hospital of Central South University, Changsha, China.
Shanghai UniCAR Therapy Biomedicine Technology Co, Ltd, Shanghai, China; Institute of Biomedical Engineering and Technology, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, China.
Cytotherapy. 2022 Oct;24(10):1026-1034. doi: 10.1016/j.jcyt.2022.05.001. Epub 2022 Jun 9.
The infusion of chimeric antigen receptor (CAR) T cells that target specific tumor-associated antigens is a promising strategy that has exhibited encouraging results in clinical trials. However, few studies have focused on the effectiveness and safety of CD20 CAR T cells in rituximab-refractory/relapsed (R/R) B-cell non-Hodgkin lymphoma (B-NHL) patients, particularly those treated with rituximab for a short time. This prospective study aimed to assess the effectiveness and toxicity of CD20 CAR T cells in R/R B-NHL patients previously treated with rituximab.
The authors conducted a prospective, single-center phase I study on the effectiveness and toxicity of CD20 CAR T cells in rituximab-treated R/R B-NHL patients (no. ChiCTR2000036350). A total of 15 patients with R/R B-NHL were enrolled between November 21, 2017, and December 1, 2021.
An overall response rate of 100% was shown in enrolled patients, with 12 (80%) achieving complete remission and three (20%) achieving partial remission for the best response. The median follow-up time was 12.4 months. Progression-free survival and overall survival were not yet reached by the data cutoff day. No patient developed grade 4 cytokine release syndrome, and only one patient had immune effector cell-associated neurotoxicity syndrome.
All enrolled B-NHL patients who were previously R/R to rituximab achieved different degrees of clinical response with tolerable toxicities. Notably, patients who had received rituximab within 3 months had a poorer prognosis.
输注靶向特定肿瘤相关抗原的嵌合抗原受体 (CAR) T 细胞是一种很有前途的策略，在临床试验中已显示出令人鼓舞的结果。然而，很少有研究关注 CD20 CAR T 细胞在利妥昔单抗难治/复发 (R/R) B 细胞非霍奇金淋巴瘤 (B-NHL) 患者中的有效性和安全性，特别是那些接受利妥昔单抗短时间治疗的患者。本前瞻性研究旨在评估 CD20 CAR T 细胞在先前接受利妥昔单抗治疗的 R/R B-NHL 患者中的有效性和毒性。
作者进行了一项前瞻性、单中心的 I 期研究，评估了 CD20 CAR T 细胞在利妥昔单抗治疗的 R/R B-NHL 患者中的有效性和毒性（编号 ChiCTR2000036350）。共纳入 15 例 R/R B-NHL 患者，入组时间为 2017 年 11 月 21 日至 2021 年 12 月 1 日。
所有入组患者的总体缓解率为 100%，其中 12 例（80%）患者达到完全缓解，3 例（20%）患者达到最佳缓解的部分缓解。中位随访时间为 12.4 个月。截至数据截止日，无患者发生 4 级细胞因子释放综合征，仅 1 例患者发生免疫效应细胞相关神经毒性综合征。
所有先前对利妥昔单抗 R/R 的 B-NHL 患者均获得不同程度的临床缓解，且毒性可耐受。值得注意的是，在 3 个月内接受利妥昔单抗治疗的患者预后较差。
